how does glp-1 work for insulin resistance Receptor Agonists Mechanism of action of GLP-1

Peptides administered via the nasal route often behave more like dietary proteins than systemic drugs due to rapid degradation and poor absorption

A Landscape Defined by Choice The framing of oral versus injectable GLP-1s as a simple binary choice is, in practice, a clinical oversimplification

Safety profiles were largely favorable, though gastrointestinal side effects and discontinuation rates varied by agent and dose

AMG 133 (now known as maridebart cafraglutide) is an optimized GIPR/GLP-1R bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR-Ab with two GLP-1 analogue agonist peptides using amino acid linkers